Merrimack Pharmaceuticals

Merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. Through systems biology, which brings together the fields of biology, computing and engineering, Merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. Such an approach has the potential to make individualized treatment of patients a reality. Merrimack's first commercial product, ONIVYDETM (irinotecan liposome injection), was approved by the U.S. FDA on October 22, 2015. With four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, Merrimack is building one of the most robust oncology pipelines in the industry.

Type
Public
HQ
Cambridge, US
Founded
2000
Employees
426 (est)+40%
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US

Key People at Merrimack Pharmaceuticals

Robert J. Mulroy

Robert J. Mulroy

President and Chief Executive Officer, Board of Directors
Gary Crocker

Gary Crocker

Chairman
Ulrik B. Nielsen

Ulrik B. Nielsen

Founder
Peter Laivins

Peter Laivins

Team Member
Edward J. Stewart

Edward J. Stewart

Team Member
William A. Sullivan

William A. Sullivan

Team Member

Merrimack Pharmaceuticals Locations

Cambridge, US

Merrimack Pharmaceuticals Metrics

Merrimack Pharmaceuticals Summary

Market capitalization

$703 M

Closing share price

$5.27
Merrimack Pharmaceuticals's latest market capitalization is $703 M.

Merrimack Pharmaceuticals Market Value History

Merrimack Pharmaceuticals Online Presence

Merrimack Pharmaceuticals News

Merrimack Pharmaceuticals Company Life

You may also be interested in